(UroToday.com) At the European Society of Medical Oncology – 2020 Virtual Congress (ESMO), Dr. Andrea Alimonti began his talk discussing the 615MO abstract: “Phase 1b/2 study of VERU-111, novel, oral tubulin inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen blocking agent”, presented by Dr. Mark Markowski.